However, topotecan alone did not show any changes in the expression of these molecules, suggesting that NF-kB/mTOR pathways play roles in chemoresistance and inhibitors combined with chemotherapy increased chemosensitivity in MYCN-amplified neuroblastoma cells. This evidence concerns the gene MTOR and neuroblastoma.